Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sangamo BioSciences Inc (NASDAQ:SGMO)

Delayed Data
As of Feb 09
 -0.11 / -1.97%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. It is engaged in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic for the treatment of HIV/AIDS. Its other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo BioSciences was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA

Contact Information

Sangamo BioSciences, Inc.
Point Richmond Tech Center II
Richmond California 94804
P:(510) 970-6000
Investor Relations:



Individual stakeholders9.27%
Other institutional46.33%
Mutual fund holders29.53%

Top Executives

Edward O. LanphierPresident, Chief Executive Officer & Director
Henry Ward WolffChief Financial Officer & Executive Vice President
Dale G. AndoChief Medical Officer & VP-Therapeutic Development
Geoffrey M. NicholExecutive Vice President-Research & Development
Fyodor UrnovSeinor Scientist